These results indicate a strong association between WMH and MCH, a common manifestation of cerebral amyloid angiopathy and ARIA-H. These results suggest that increased WMH volume may represent an early sign of vessel amyloidosis, likely prior to the emergence of MCH. 4 key findings →
Design: longitudinal study
Evidence: high
Full summary, score breakdown and related studies →
Original source
77/100
✓ Peer-reviewed
alzhub usefulness score 77 out of 100.
·
JAMA neurology
·
2019-08-01
An antecedent rise in Aβ was associated with subsequent changes in tau (1.07 flortaucipir standardized uptake value ratios [SUVr]/PiB-SUVr; 95% CI, 0.13-3.46; P = .02). 5 key findings →
Design: cohort study
Participants: 279
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Noninvasive biomarkers of early neuronal injury may help identify cognitively normal individuals at risk of developing Alzheimer's disease (AD). 2 key findings →
Design: longitudinal study
Participants: 196
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA neurology
·
2018-09-01
The mean (SD) age was 73.7 (6.0) years, and the mean (SD) follow-up time was 3.7 (1.2) years. 3 key findings →
Design: longitudinal study
Participants: 223
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Advances in molecular positron emission tomography (PET) have enabled anatomic tracking of brain pathology in longitudinal studies of normal aging and dementia, including assessment of the central model of Alzheimer's disease (AD) pathogenesis, according to which TAU pathology begins focally but expands catastrophically under the influence of amyloid-β (Aβ) pathology to mediate neurodegeneration and cognitive decline. 2 key findings →
Design: longitudinal study
Participants: 104
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Vascular risks interact with subthreshold levels of Aβ to promote cognitive decline, partially by accelerating early neocortical tau accumulation. 4 key findings →
Design: longitudinal study
Participants: 175
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
Neurology
·
2023-11-08
In older adults, longitudinal hippocampal atrophy is associated with cognitive decline, independently of Aβ or tau, suggesting that non-AD pathologies (e.g., TDP-43, vascular) may contribute to hippocampal-mediated cognitive decline. 4 key findings →
Design: cohort study
Participants: 283
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
Neurology
·
2021-06-14
In preclinical Alzheimer disease, entorhinal hypometabolism is a strong and independent predictor of subsequent cognitive decline, making FDG a potentially useful biomarker to increase power in clinical trials. 5 key findings →
Design: cohort study
Participants: 131
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
Neurology
·
2017-06-07
In clinically normal older adults, lower functional connectivity predicted more rapid decline in PACC scores over time, particularly when coupled with increased Aβ burden. 2 key findings →
Design: longitudinal study
Participants: 237
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cross-sectional functional magnetic resonance imaging studies using a memory task in patients with mild cognitive impairment have produced discordant results, with some studies reporting increased hippocampal activity--consistent with findings in genetic at-risk populations--and other studies reporting decreased hippocampal activity, relative to normal controls. 3 key findings →
Design: cross-sectional
Participants: 33
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
JAMA neurology
·
2024-08-01
Of 4413 individuals (mean [SD] age, 71.27 [4.66] years, 2617 women [59.3%]), mean Aβ-PET was elevated in individuals with history of memory impairment in both parents (n = 455; mean [SD] standardized uptake value ratio [SUVR] = 1.12 [0.19]; Wilcoxon P = 1.1 × 10-5) and in those with only maternal history (n = 1772; mean [SD] SUVR = 1.10 [0.19]; Wilcoxon P = 2.70 × 10-5) compared with those with only paternal history (n = 632; mean [SD] SUVR = 1.08 [0.18]; Wilcoxon P = 1.1 × 10-5) or no family history (n = 1554; mean [SD] SUVR = 1.08 [0.19]; Wilcoxon P = 1.1 × 10-5). 3 key findings →
Design: cross-sectional
Participants: 455
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Animal models of Alzheimer's disease have suggested that tau pathology propagation, facilitated by amyloid pathology, may occur along connected pathways. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
59/100
✓ Peer-reviewed
alzhub usefulness score 59 out of 100.
·
Neurology
·
2020-11-16
These optimized thresholds can help to inform future research and clinical trials targeting early Aβ. 2 key findings →
Participants: 342
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
59/100
✓ Peer-reviewed
alzhub usefulness score 59 out of 100.
·
JAMA neurology
·
2014-11-01
The co-occurrence of Aβ and ND accelerates cognitive decline in CN individuals. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Disruption of functional connectivity between brain regions may represent an early functional consequence of β-amyloid pathology prior to clinical Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
PET can evaluate amyloid expansion from cortex to subcortex. 1 key finding →
Participants: 1,433
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
D-CAA M + showed greater age-dependent FLR PiB retention (p - , and serially imaged asymptomatic M + demonstrated greater longitudinal increases (p = 0.004). 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
55/100
✓ Peer-reviewed
alzhub usefulness score 55 out of 100.
·
JAMA neurology
·
2015-08-01
Similar to findings in adult mutation carriers, in the later preclinical and clinical stages of ADAD, mutation-carrying children were distinguished from control individuals by significantly higher plasma Aβ1-42 levels (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P Conclusions and relevance Children at genetic risk for ADAD have functional and structural brain changes and abnormal levels of plasma Aβ1-42. 2 key findings →
Design: cross-sectional
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
55/100
✓ Peer-reviewed
alzhub usefulness score 55 out of 100.
·
Neurology
·
2015-05-01
Our objective was to investigate cross-sectional associations between odor identification ability and imaging biomarkers of neurodegeneration and amyloid deposition in clinically normal (CN) elderly individuals, specifically testing the hypothesis that there may be an interaction between amyloid deposition and neurodegeneration in predicting odor identification dysfunction. 1 key finding →
Design: cross-sectional
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
Neurology
·
2020-04-09
The presubiculum captures unique AD-related biological variation that is not reflected in total hippocampal volume. 2 key findings →
Participants: 127
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Tau vulnerability in women is not just limited to the medial temporal lobe and significantly contributed to greater risk of faster cognitive decline. 2 key findings →
Participants: 55
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
These results suggest a potential link between vascular risk and tau pathology in preclinical AD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Future longitudinal studies examining the association of more severe depressive symptoms and cerebral tau accumulation are needed to substantiate this finding and to guide prevention and treatment in AD. 4 key findings →
Design: cross-sectional
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Animal studies demonstrate that hyperactive neurons facilitate early accumulation and spread of tau and amyloid-β proteins in the pathological cascade of Alzheimer's disease (AD). 3 key findings →
Participants: 120
Evidence: low
Full summary, score breakdown and related studies →
Original source
Age-related alterations in brain structure and function have been challenging to link to cognition due to potential overlapping influences of multiple neurobiological cascades. 3 key findings →
Participants: 186
Evidence: low
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 30,180 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.